TPS — Transcranial Pulsed Stimulation
NEUROLIT technology approved in Europe as support for mild to moderate cognitive impairment associated with Alzheimer's disease. The indication is decided after neurological assessment.
About the treatment
NEUROLIT technology approved in Europe as support for mild to moderate cognitive decline associated with Alzheimer's disease. The indication is determined after neurological assessment.
How it works
Non-invasive treatment, no sedation required. Typically 6 sessions over 2 weeks.
Indications
Mild to moderate cognitive impairment
Early-stage Alzheimer's disease
Contraindications
Cranial implants
Unstable psychiatric disorders
Frequently asked questions
The treatment is well tolerated. The intensity is adjusted to the individual sensitivity of each patient.
The number of sessions depends on the diagnosis. After the first assessment, the doctor will indicate the recommended plan for your case.
